

BELLUS HEALTH INC. (BLU- TSX) – \$1.62

- *BELLUS Health is a biotechnologies development company advancing BLU-5937 as a treatment for Chronic cough.*
- *Well financed ... recently closed a 35 Million PP offering lead by Bloom Burton securities*
- *Phase 2 could be initiated by mid-April 2019*
- *Senior Analyst at Baird Equity research has a 4\$ Target*
- *Insiders own over 30% ... MI3 first Tech note on BLU at \$0.54 last May*
- *BLU traded over 5 Million shares in the last month between \$1.24 and \$1.66*
- *Support: S2; \$1.33 - S1; \$1.41 Resistance: R1; \$1.66 – R2; \$1.75 Breakout*



[Annotate](#) [Print](#) [Share](#) [Permalink](#) [Instructions](#) [Report Problems](#)

Chart Attributes

PLEASE DO YOUR DUE DILIGENCE

Disclaimer:

This MI3 Technical Note produced by MI3 Communications Financières is neither an offer to sell, nor the solicitation of an offer to buy any of the securities discussed therein. The information contained is prepared by MI3, emanating from sources deemed to be reliable. MI3 Communications Financières makes no representations or warranties with respect to the accuracy, correctness or completeness of such information. MI3 Communications Financières accepts no liability whatsoever for any loss arising from the use of the information contained therein. Please take note that for compliance purposes, all directors, consultants or employees of MI3 Communications Financières are prohibited from trading the securities of the company and MI3 Communications Financières is a shareholder and do not intend to sell any shares during the distribution of this report.